Daily Intelligence Brief
Depo-Provera, Hair Relaxer Drive 131 New Filings As Ozempic NAION Docket Stalls
The Depo-Provera Products Liability Litigation (MDL 3140) (N.D. Fla., Judge M. Casey Rodgers) and Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) (N.D. Ill., Judge Mary M. Rowland) combined for 131 new federal complaints in the past week — more than one-third of all tracked mass tort filings — while the Ozempic and Other GLP-1 RA Medications Products Liability Litigation (MDL 3163) (E.D. Pa., Judge Karen Marston) saw its NAION vision-loss docket add just six cases despite earlier momentum. The Depo-Provera docket's 68 new meningioma claims maintain its position as the fastest-growing pharmaceutical MDL, with roughly 3,490 pending actions per JPML's April 1 report plus significant transfer lag. Hair Relaxer's 63 filings mark its strongest weekly showing since March, with Colorado's pending mandatory warning label legislation providing tailwinds. Meanwhile, the Uber Technologies Inc. Sexual Assault Litigation (MDL 3084) (N.D. Cal., Judge Jacqueline Scott Corley) absorbed 35 coordinated California filings — five times the volume of rival Lyft Assault Litigation (MDL 3171) — suggesting plaintiff firms are prioritizing the larger, more established ride-share assault docket.Suboxone Teeth MDL Sees First Ohio Federal Filings As Dental Decay Claims Expand
The Suboxone Sublingual Film Products Liability Litigation (MDL 3092) (N.D. Ohio, Judge J. Philip Calabrese) registered its first post-centralization federal complaints with Bane v. Indivior Inc. (1:26-sf-65040) and Abernathy v. Indivior, Inc. (1:26-sf-65041), ending a quiet start for the buprenorphine dental injury docket. The filings allege Indivior's sublingual film caused severe tooth decay and oral infections — claims that survived initial dismissal motions in state court and now face consolidated federal review. Judge Calabrese has yet to issue a case management order, but the Ohio filings signal plaintiff firms are moving past administrative delays that stalled early centralization. The MDL covers allegations that Indivior failed to warn prescribers and patients about dental risks until a 2022 label update, with potential exposure across hundreds of thousands of long-term users.Bard Hernia Mesh MDL Absorbs First Southern Ohio Filings As Parallel Covidien Docket Expands
The Bard Hernia Mesh Products Liability Litigation (MDL 2846) (S.D. Ohio, Judge Edmund A. Sargus Jr.) added McCracken v. Bard (2:26-cv-00389) and Glover v. C.R. Bard Inc (2:26-cv-00392) — its first tracked federal complaints in the past week — as hernia mesh litigation fragments across multiple MDLs and manufacturers. The filings join roughly 20,000 pending Bard claims already in the MDL, which has produced mixed bellwether results and no global settlement. The activity contrasts with Covidien Hernia Mesh Products Liability Litigation (MDL 3029) (D. Mass., Judge Patti B. Saris), where three new filings including Texas's Jarmon v. Medtronic USA, Inc. (4:26-cv-00314) suggest plaintiff firms are diversifying across manufacturers amid stalled consolidation talks. Neither MDL has active bellwether trials scheduled, leaving both dockets in document-heavy discovery phases with no near-term resolution catalyst.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
